Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Events and Conferences
  • Home
  • Privacy Policy
  • Subscribe
  • Terms and Conditions
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • Press Releases

Cytokinetics Issues Inducement Grants Under Nasdaq Rule 5635(c)(4)

  • The Pharma Data
  • May 17, 2025

Cytokinetics Issues Equity Awards as Employment Inducements Under Nasdaq Rule 5635(c)(4), Advances Momentum in Cardiovascular Drug Development Cytokinetics, Incorporated (Nasdaq: CYTK), a leading biopharmaceutical company dedicated to developing novel therapies…

Read MoreCytokinetics Issues Inducement Grants Under Nasdaq Rule 5635(c)(4)
  • News

One World for Health: 78th World Health Assembly Set to Convene from 19–27 May 2025

  • The Pharma Data
  • May 17, 2025

One World for Health: Inside the 78th World Health Assembly and the Future of Global Public Health From May 19 to 27, 2025, Geneva, Switzerland, will once again become the…

Read MoreOne World for Health: 78th World Health Assembly Set to Convene from 19–27 May 2025
  • News

WHO Partners with Universal Postal Union to Expand Global Access to Eyeglasses

  • The Pharma Data
  • May 17, 2025

WHO and Universal Postal Union Launch Global Initiative to Expand Access to Eye Care Through Postal Networks In a groundbreaking move to address the global burden of vision impairment, the…

Read MoreWHO Partners with Universal Postal Union to Expand Global Access to Eyeglasses
  • News

30 Years of Progress: Mobilizing Health to End Violence Against Women and Girls

  • The Pharma Data
  • May 17, 2025

30 Years of Progress: Mobilizing the Health Sector to End Violence Against Women and Girls In the three decades since the landmark Beijing Platform for Action on Women was adopted…

Read More30 Years of Progress: Mobilizing Health to End Violence Against Women and Girls
  • News

BioMarin Strengthens Enzyme Capabilities Through $270 Million Acquisition of Inozyme

  • The Pharma Data
  • May 17, 2025

BioMarin Bolsters Enzyme Therapy Portfolio with $270 Million Acquisition of Rare Disease Specialist Inozyme Pharma BioMarin Pharmaceutical, a leading biotech company focused on rare diseases and enzyme replacement therapies, announced…

Read MoreBioMarin Strengthens Enzyme Capabilities Through $270 Million Acquisition of Inozyme
  • News

Incyte Secures FDA Approval for PD-1 Inhibitor in First-Line Treatment of Anal Cancer

  • The Pharma Data
  • May 17, 2025

Incyte’s Zynyz Secures First-Line Approval in Anal Cancer, Marking a Milestone for PD-1 Therapy in Rare Tumor Type In a significant development for the treatment of a rare and underserved…

Read MoreIncyte Secures FDA Approval for PD-1 Inhibitor in First-Line Treatment of Anal Cancer
  • News

Teen Scientists Win Over $9M at 75th Regeneron ISEF 2025

  • The Pharma Data
  • May 17, 2025

Global Youth Scientists Shine at 75th Regeneron ISEF, Sharing Over $9 Million in Prizes In a celebration of youthful brilliance, scientific curiosity, and international collaboration, the 75th Annual Regeneron International…

Read MoreTeen Scientists Win Over $9M at 75th Regeneron ISEF 2025
  • News

EU Approves Bristol Myers’ Opdivo Regimen for Resectable High-Risk NSCLC with PD-L1 ≥1%

  • The Pharma Data
  • May 17, 2025

European Commission Grants Approval to Bristol Myers Squibb’s Perioperative Opdivo Regimen for Resectable, High-Risk NSCLC with PD-L1 Expression ≥1% Bristol Myers Squibb has announced that the European Commission (EC) has…

Read MoreEU Approves Bristol Myers’ Opdivo Regimen for Resectable High-Risk NSCLC with PD-L1 ≥1%
  • Press Releases

Merck to Present New PAH Data at ATS 2025 Conference

  • The Pharma Data
  • May 17, 2025

Merck to Present Robust Set of Pulmonary Arterial Hypertension Data at ATS 2025, Underscoring Long-Term Commitment to Innovation and Patient Outcomes Merck , known as MSD outside the United States…

Read MoreMerck to Present New PAH Data at ATS 2025 Conference
  • Press Releases

Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down

  • The Pharma Data
  • May 17, 2025

Leadership Transition at Novo Nordisk: CEO Lars Fruergaard Jørgensen to Step Down Amid Market Headwinds and Strategic Realignment In a significant leadership transition, Novo Nordisk A/S announced that Lars Fruergaard…

Read MoreNovo Nordisk CEO Lars Fruergaard Jørgensen to Step Down
  • Press Releases

FDA Approves Zynyz® as First-Line Treatment for Advanced Anal Cancer in the U.S.

  • The Pharma Data
  • May 16, 2025

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr), the First and Only Approved First-Line Treatment for Advanced Anal Cancer in the U.S. Incyte Corporation (Nasdaq: INCY), a global biopharmaceutical company focused…

Read MoreFDA Approves Zynyz® as First-Line Treatment for Advanced Anal Cancer in the U.S.
  • Press Releases

Merck Demonstrates Resilience with Continued Growth

  • The Pharma Data
  • May 16, 2025

Merck Delivers Resilient Growth Across All Divisions in Q1 2025, Advances Strategic Expansion with SpringWorks Acquisition Merck, the global science and technology powerhouse, began 2025 on strong footing, demonstrating solid…

Read MoreMerck Demonstrates Resilience with Continued Growth
Next

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: [email protected]

Latest Posts

  • Cytokinetics Issues Inducement Grants Under Nasdaq Rule 5635(c)(4)
  • One World for Health: 78th World Health Assembly Set to Convene from 19–27 May 2025
  • WHO Partners with Universal Postal Union to Expand Global Access to Eyeglasses
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2025 | The Pharma Data | All Rights Reserved.